Annual Total Debt
$586.04 M
-$177.35 M-23.23%
December 31, 2023
Summary
- As of February 7, 2025, PCRX annual total debt is $586.04 million, with the most recent change of -$177.35 million (-23.23%) on December 31, 2023.
- During the last 3 years, PCRX annual total debt has risen by +$44.92 million (+8.30%).
- PCRX annual total debt is now -48.08% below its all-time high of $1.13 billion, reached on December 31, 2021.
Performance
PCRX Total Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Debt
$644.42 M
-$4.17 M-0.64%
September 30, 2024
Summary
- As of February 7, 2025, PCRX quarterly total debt is $644.42 million, with the most recent change of -$4.17 million (-0.64%) on September 30, 2024.
- Over the past year, PCRX quarterly total debt has increased by +$54.13 million (+9.17%).
- PCRX quarterly total debt is now -42.91% below its all-time high of $1.13 billion, reached on December 31, 2021.
Performance
PCRX Quarterly Total Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Debt Formula
Total Debt = Short Term Debt + Long Term Debt
PCRX Total Debt Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -23.2% | +9.2% |
| 3 y3 years | +8.3% | -35.6% |
| 5 y5 years | +101.4% | -35.6% |
PCRX Total Debt Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -48.1% | at low | -42.9% | +10.8% |
| 5 y | 5-year | -48.1% | +66.5% | -42.9% | +83.1% |
| alltime | all time | -48.1% | -100.0% | -42.9% | -100.0% |
Pacira BioSciences Total Debt History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $644.42 M(-0.6%) |
| Jun 2024 | - | $648.60 M(+11.5%) |
| Mar 2024 | - | $581.78 M(-0.7%) |
| Dec 2023 | $586.04 M(-23.2%) | $586.04 M(-0.7%) |
| Sep 2023 | - | $590.30 M(-4.9%) |
| Jun 2023 | - | $620.71 M(-0.7%) |
| Mar 2023 | - | $625.16 M(-18.1%) |
| Dec 2022 | $763.39 M(-32.4%) | $763.39 M(-7.1%) |
| Sep 2022 | - | $821.64 M(-1.2%) |
| Jun 2022 | - | $831.36 M(-17.0%) |
| Mar 2022 | - | $1.00 B(-11.3%) |
| Dec 2021 | $1.13 B(+108.6%) | $1.13 B(+103.6%) |
| Sep 2021 | - | $554.56 M(+1.0%) |
| Jun 2021 | - | $549.27 M(+0.9%) |
| Mar 2021 | - | $544.15 M(+0.6%) |
| Dec 2020 | $541.13 M(+53.8%) | $541.13 M(+0.9%) |
| Sep 2020 | - | $536.37 M(+35.6%) |
| Jun 2020 | - | $395.69 M(+11.7%) |
| Mar 2020 | - | $354.24 M(+0.7%) |
| Dec 2019 | $351.92 M(+21.0%) | $351.92 M(+1.7%) |
| Sep 2019 | - | $346.01 M(+0.8%) |
| Jun 2019 | - | $343.40 M(+4.3%) |
| Mar 2019 | - | $329.24 M(+13.2%) |
| Dec 2018 | $290.93 M(+5.2%) | $290.93 M(+1.3%) |
| Sep 2018 | - | $287.23 M(+1.3%) |
| Jun 2018 | - | $283.59 M(+1.3%) |
| Mar 2018 | - | $280.01 M(+1.3%) |
| Dec 2017 | $276.50 M(+154.3%) | $276.50 M(+1.3%) |
| Sep 2017 | - | $273.04 M(+1.3%) |
| Jun 2017 | - | $269.65 M(+1.1%) |
| Mar 2017 | - | $266.75 M(+145.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2016 | $108.74 M(+4.5%) | $108.74 M(+1.1%) |
| Sep 2016 | - | $107.56 M(+1.1%) |
| Jun 2016 | - | $106.39 M(+1.1%) |
| Mar 2016 | - | $105.22 M(+1.1%) |
| Dec 2015 | $104.04 M(+0.9%) | $104.04 M(-0.8%) |
| Sep 2015 | - | $104.91 M(+1.0%) |
| Jun 2015 | - | $103.89 M(-0.2%) |
| Mar 2015 | - | $104.14 M(+1.0%) |
| Dec 2014 | $103.10 M(+4.2%) | $103.10 M(+1.0%) |
| Sep 2014 | - | $102.06 M(+1.0%) |
| Jun 2014 | - | $101.03 M(+1.0%) |
| Mar 2014 | - | $100.00 M(+1.0%) |
| Dec 2013 | $98.96 M(+292.8%) | $98.96 M(+1.1%) |
| Sep 2013 | - | $97.93 M(+1.1%) |
| Jun 2013 | - | $96.89 M(+1.1%) |
| Mar 2013 | - | $95.86 M(+280.5%) |
| Dec 2012 | $25.19 M(-1.5%) | $25.19 M(-5.5%) |
| Sep 2012 | - | $26.65 M(+8.0%) |
| Jun 2012 | - | $24.67 M(-10.8%) |
| Mar 2012 | - | $27.66 M(+8.1%) |
| Dec 2011 | $25.58 M(+2.1%) | $25.58 M(+0.4%) |
| Sep 2011 | - | $25.47 M(-11.9%) |
| Jun 2011 | - | $28.91 M(+15.0%) |
| Mar 2011 | - | $25.14 M(+0.3%) |
| Dec 2010 | $25.05 M(>+9900.0%) | $25.05 M(-54.9%) |
| Sep 2010 | - | $55.55 M(+887.5%) |
| Jun 2010 | - | $5.63 M(>+9900.0%) |
| Mar 2010 | - | $0.00(0.0%) |
| Dec 2009 | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2009 | - | $0.00 |
| Dec 2008 | $0.00 | - |
FAQ
- What is Pacira BioSciences annual total debt?
- What is the all time high annual total debt for Pacira BioSciences?
- What is Pacira BioSciences annual total debt year-on-year change?
- What is Pacira BioSciences quarterly total debt?
- What is the all time high quarterly total debt for Pacira BioSciences?
- What is Pacira BioSciences quarterly total debt year-on-year change?
What is Pacira BioSciences annual total debt?
The current annual total debt of PCRX is $586.04 M
What is the all time high annual total debt for Pacira BioSciences?
Pacira BioSciences all-time high annual total debt is $1.13 B
What is Pacira BioSciences annual total debt year-on-year change?
Over the past year, PCRX annual total debt has changed by -$177.35 M (-23.23%)
What is Pacira BioSciences quarterly total debt?
The current quarterly total debt of PCRX is $644.42 M
What is the all time high quarterly total debt for Pacira BioSciences?
Pacira BioSciences all-time high quarterly total debt is $1.13 B
What is Pacira BioSciences quarterly total debt year-on-year change?
Over the past year, PCRX quarterly total debt has changed by +$54.13 M (+9.17%)